Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?
Misbah Nizamani · 2024
Read Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients? by Misbah Nizamani (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11708946.txt.
Description
Misbah Nizamani asked whether a multiple sclerosis drug can trigger sarcoidosis in two thousand twenty-four. Sarcoidosis grows clusters of immune cells in organs. Its cause remains unknown to medicine. Interferon drugs are known to provoke it sometimes. A few patients developed it after alemtuzumab therapy. That antibody strips a marker from immune cells.
It treats relapsing multiple sclerosis and some leukemias. Cases surfaced a few years into treatment. Most patients responded well to sarcoidosis care. Some needed no treatment at all. The pattern raises a caution flag for prescribers. New lung or skin signs deserve a second look. Awareness, not alarm, is the author's message.
Catalog record
| CREATOR | Misbah Nizamani |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |